Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy

AKIN TELLİ T., ÖZTÜRK M. S., Alan O., Hasanov R., KÖSTEK O., Arikan R., ...Daha Fazla

FUTURE ONCOLOGY, cilt.18, ss.2425-2439, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/fon-2021-1322
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2425-2439
  • Anahtar Kelimeler: adjuvant endocrine therapy, breast cancer, FACT-B, FACT-G, quality-of-life, FUNCTIONAL ASSESSMENT, POSTMENOPAUSAL WOMEN, SYMPTOM BURDEN, FACT-B, TAMOXIFEN, SURVIVORS, EXEMESTANE, OUTCOMES, IMPACT, TRIAL
  • Marmara Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study was to investigate quality-of-life (QoL) in breast cancer (BC) patients treated with adjuvant endocrine therapy (AET). Methods: We designed a cross-sectional study of 233 BC patients treated with AET and used the Functional Assessment of Cancer Therapy - Breast questionnaire. Results: No significant difference was observed between endocrine agents. Duration of AET did not affect QoL. In the entire cohort, multivariate analysis determined age (p = 0.034) and switching treatment from tamoxifen to aromatase inhibitors (p = 0.049) as significant positive coefficients of QoL, while comorbidity (p = 0.072) tended to be associated with lower scores. Education level (p = 0.001) and chemotherapy (p = 0.04) were significant predictors of QoL in the tamoxifen group, while comorbidity (p = 0.04), surgery type (p = 0.02), radiotherapy (p = 0.006) and stage (p = 0.009) had a significant impact on QoL in aromatase inhibitors group. Conclusion: Evaluating the well-being of BC patients by QoL questionnaires is of great importance to identify particular subgroups that may require supportive care.